OBJECTIVE

To analyze the long-term outcomes in patients with hypertrophic cardiomyopathy (HCM) after ethanol septal ablation (ESA).

MATERIAL AND METHODS

There were 25 ESA procedures in patients with HCM and left ventricular outflow tract (LVOT) obstruction between January 2018 and September 2022. Mean age of patients was 61 [43; 80] years, women prevailed (60%). All patients had HCM with LVOT obstruction and peak pressure gradient ≥50 mm Hg. Before ESA, patients underwent balloon occlusion of septal branch, and intervention was performed only when peak pressure gradient decreased by 50% or more.

RESULTS

One patient died from tumor of the frontal and temporal lobe. Another patient experienced non-fatal stroke. There were no repeated interventions on LVOT, myocardial infarctions or pacemaker implantations. Survey revealed that 5 (24%) patients had recurrence of angina pectoris, 11 (52%) — shortness of breath, 8 (38%) — fatigue despite low peak pressure gradient (<35 mm Hg) after ESA.

CONCLUSION

Taking into account the long-term results in this study (22 [7; 40] months), we can emphasize high effectiveness and safety of ESA in these patients. Together with literature data, it is a serious argument in favor of this technology in various hospitals engaged in high-tech medical care for patients with HCM.